Document:

Employment Offer Letter Agreement, dated November 11, 2009

 Exhibit 10.48 

 

 

 November 5, 2009 
 Alan Cohen, M.D. 
 2401 Sharon Oaks Drive 
 Menlo Park, CA 94025 
 (650) 233-9297 

 

	 	Re:	Employment with InterMune, Inc. 

 Dear
Alan: 
 On behalf of InterMune, Inc., I am pleased to extend to you this official offer of employment with InterMune as Senior
Vice President, Medical Affairs, reporting to Dan Welch, President and Chief Executive Officer, in our Brisbane, California office beginning on November 30, 2009. InterMune may change your position, duties, supervisor and work location from
time to time as it deems appropriate. This position is a full time, exempt position. 
 Your employment is subject to proof of
your legal right to work in the United States, and to your completing the INS Employment Eligibility Verification Form I-9. Your employment also is subject to successful verification of your professional references, and to our standard
pre-employment process, which includes completion of an employment application and successful completion of a standard background check. 

Compensation 
 If you accept
this offer and begin employment, you will receive an initial base salary of $25,833.33 per month (equivalent to $310,000 per year), paid on a semi-monthly basis on our regular paydays. Deductions required by law or authorized by you will be taken
from each paycheck. 
 You also will receive a sign-on bonus of $45,000 (less all required deductions), to be paid as follows:
$30,000 after your first day of employment and $15,000 no later than 60 days following your first day of employment upon your successful completion of performance milestones mutually agreed upon by you and Dan Welch. 

Additionally, you will be eligible to participate in our discretionary incentive bonus program designed to provide a financial reward for
achieving performance goals. The incentive plan will be based on two criteria: your individual performance against your goals as determined 

 Alan Cohen, M.D. 
 November 5, 2009 
  Page
 2
 
  

 
by your manager and InterMune’s performance as determined by InterMune’s senior management. For 2010, your target bonus will be 35% of your base pay. 

You also will be eligible to participate in InterMune’s Equity Incentive Plan. Following commencement of your employment, the grant
of an option to purchase up to 90,000 shares of Common Stock under InterMune’s Equity Incentive Plan will be recommended to the Compensation Committee of the InterMune Board of Directors on your behalf. All option grants are subject to final
approval by the Compensation Committee of the InterMune Board of Directors. The option shares will vest over a period of four years beginning on the date of your employment and the option exercise price will be the NASDAQ closing price of
InterMune’s common stock on the fifth business day of the month following the month in which you begin employment (in your case, the date is to be determined based on your Date of Hire). The exercise of any options will be subject in all
respects to the terms of your stock option agreement and the Equity Incentive Plan. 
 Although you will not yet have completed
a full year of employment, for 2010, you will be eligible for an annual equity grant on the same terms and conditions as all other members of InterMune’s Executive Committee. 
 Employee Benefits 
 As a full-time employee, you will be eligible for paid
time-off benefits, such as sick leave and holidays, in accordance with our policies for similarly situated employees. You also will be eligible to participate in InterMune’s employee benefit plans, in accordance with the terms and eligibility
requirements of those plans. Currently, InterMune maintains group health insurance, vision and dental plans, a short and long-term disability plan, a Flexible Spending Account plan, a group Life Insurance and AD&D plan, a 401(k) savings plan, a
Long Term Care plan and an Employee Stock Purchase Plan. 
 InterMune reserves the right to modify, amend or discontinue any
benefit plan at any time, in its sole discretion. You may receive such other benefits as we may determine from time to time, in our sole discretion. 
 Benefits upon Separation 
 Severance Pay in the Event of Termination (Not For
Cause) Absent a Change in Control of InterMune. As a member of the Company’s Executive Committee, you will be entitled to the following benefits in the event your employment is terminated other than for “Cause” or in the event of
a “Change in Control” of InterMune (as those terms are defined below). Although you at all times will remain an at-will employee of InterMune, InterMune agrees that in the event you are terminated by the Company other than for
“Cause” in the absence of a “Change in Control” of InterMune, you will receive the following benefits within fourteen (14) days after receipt by the Company of a general release duly signed by the you that releases the
Company from all of your actual or potential claims against InterMune: 

 Alan Cohen, M.D. 
 November 5, 2009 
  Page
 3
 
  

	 	•	 	 If you have completed less than one (1) full year of service, you will receive six (6) months’ base salary at your final rate of pay,
six (6) months benefits continuation (i.e., Company-provided COBRA payments or equivalent), and six (6) months immediate acceleration of vesting of each of your outstanding equity grants, whether stock options or restricted shares

  

	 	•	 	 If you have completed at least one (1) year but less than two (2) years of service, you will receive nine (9) months’ base salary
at your final rate of pay, nine (9) months benefits continuation (i.e., Company-provided COBRA payments or equivalent), and nine (9) months immediate acceleration of vesting of each of your outstanding equity grants, whether stock
options or restricted shares 

  

	 	•	 	 If you have completed two (2) years of service or more, you will receive twelve (12) months’ base salary at your final rate of pay,
twelve (12) months benefits continuation (i.e., Company-provided COBRA payments or equivalent), and twelve (12) months immediate acceleration of vesting of each of your outstanding equity grants, whether stock options or restricted
shares 

  

	 	•	 	 If such termination not for Cause occurs in the second half of the calendar year, you also will receive a pro rata share of your target bonus
for that year. 

 The acceleration of vesting provided for in this section of this agreement is intended to be in lieu of any
acceleration rights provided in any operative Stock Option Agreement you may sign, and in addition to any acceleration rights provided in the operative Stock Plan documents. All other terms and conditions applicable to your equity grants,
e.g., with regard to exercise after termination, forfeiture, etc., will continue to be governed by the operative Stock Option Agreement and Stock Plan document. Cash compensation required to be paid pursuant to this section of this Agreement
will be paid either in a single lump-sum payment or ratably on a monthly basis over the severance period, in the Company’s sole discretion. 
 Compensation upon Change in Control of InterMune. In the event of a Change in Control of the Company that results in: (i) your termination without Cause, or (ii) your resignation for
“Good Reason,” which for purposes of this Agreement shall mean either (a) a material diminution in your duties, title or compensation, or (b) a requirement that you relocate more than 80 km (50 miles) from your then-current
employment location, any of which event occurs within one (1) year of the change in control (a “Triggering Event”), you will receive the following benefits within fourteen (14) days after receipt by the Company of a general
release duly signed by the you that releases the Company from all of your actual or potential claims against InterMune: 

 Alan Cohen, M.D. 
 November 5, 2009 
  Page
 4
 
  

 (a) Cash Compensation: Two (2) years base salary at your final rate of pay
and two (2) years benefits continuation (i.e., Company-provided COBRA payments or equivalent). If a Triggering Event occurs in the second half of the calendar year, you also will receive a pro rata share of your target bonus for
that year. 
 (b) Options or Restricted Share Grants: Vesting of all outstanding equity grants (including InterMune stock
option grants, InterMune restricted stock grants, and any grants made by the acquiring entity) will immediately accelerate. The acceleration of vesting provided for in this section of this Agreement is intended to be in lieu of any acceleration
rights provided in the operative Stock Option Agreement, and in addition to any acceleration rights provided in the operative Stock Plan document. All other terms and conditions applicable to your equity grants, e.g., with regard to exercise
after termination, forfeiture, etc., will continue to be governed by the operative Stock Option Agreement and Stock Plan documents. 
 Definitions 
 For purposes of this agreement, “Cause” shall mean
any of the following: 
  

	 	•	 	 Willful refusal to follow lawful and reasonable corporate policy or Chief Executive Officer directives; or 

 

	 	•	 	 Willful failure, gross neglect or refusal to perform duties; or 

 

	 	•	 	 Willful act that intentionally or materially injures the reputation or business of the Company; or 

 

	 	•	 	 Willful breach of confidentiality that has a material adverse affect on the Company; or 

 

	 	•	 	 Fraud or embezzlement; or 

  

	 	•	 	 Indictment for criminal activity. 

 For purposes of this Agreement, “Change in Control” shall mean any of the following: 
  

	 	•	 	 A sale, lease or other disposition of all or substantially all of the securities or assets of the Company; or 

 

	 	•	 	 A merger or consolidation in which the Company is not the surviving corporation; or 

 

	 	•	 	 A reverse merger in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger are
converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise. 

Employment with InterMune is at will. “Employment at will” means that you are free to resign from your employment at any time,
for any reason or no reason, with or without cause and with or without notice. Similarly, InterMune may terminate your employment at any time for any legal reason, with or without cause and with or without notice. By accepting this offer of
employment, you agree that your employment is at will, and acknowledge that no one, other than 

 Alan Cohen, M.D. 
 November 5, 2009 
  Page
 5
 
  

 
the Chief Executive Officer of InterMune, has the authority to promise you anything to the contrary and that any such agreement must be in writing and signed by both you and the Chief Executive
Officer of InterMune to be effective. 
 We believe that your employment with InterMune requires a full-time commitment.
Employment with any other entity, or for yourself in competition with InterMune, is not permitted unless expressly authorized by InterMune in writing. 
 As an InterMune employee, you will be expected to abide by company rules and regulations and acknowledge in writing that you have read and agree to abide by the provisions of InterMune’s Employee
Handbook. 
 During the course of your employment, you may create, develop or have access to confidential information belonging
to InterMune, including trade secrets and proprietary information, such as clinical and other scientific data, customer information, business plans, marketing plans, unpublished financial information, software, source codes, and personnel
information. You agree that as a condition of your employment with InterMune, you will sign and comply with the enclosed InterMune Proprietary Information and Inventions Agreement, which contains certain commitments regarding confidentiality. By
accepting employment with InterMune, you also agree to keep all InterMune information strictly confidential, and not to use it or disclose it to any person or entity, except as is necessary in the ordinary course of performing your work. You further
acknowledge that your obligation to protect our confidential information from disclosure exists both during your employment and after it ends. You also agree that at the termination of your employment, for any reason, you will return to us all
copies (including electronic copies) of any documents or other materials you have that refer to or contain InterMune’s confidential information, including notebooks, manuals, letters and customer lists. 

In your work for InterMune, you will be expected not to use or disclose any confidential information, including trade secrets, of any
former employer or other person to whom you have an obligation of confidentiality. You agree to act in accordance with any valid non-disclosure agreements to which you may be subject. You will be expected to use only that information which is
generally known and used by persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by InterMune. By accepting this
offer of employment, you acknowledge that you will be able to perform your duties within these guidelines. You further agree that you will not bring onto InterMune’s premises any unpublished documents or property belonging to any former
employer or other person to whom you have an obligation of confidentiality. 
 You also agree, if you accept this offer of
employment, that for a period of two years after your employment ends, you will not solicit any InterMune employee or consultant to leave his or her employment or consulting relationship with InterMune in order to begin employment or a consulting
relationship with any company or business in actual or potential competition with InterMune. 

 Alan Cohen, M.D. 
 November 5, 2009 
  Page
 6
 
  

 The terms described in this letter, together with your Proprietary Information and
Inventions Agreement, replace all prior agreements, understandings, and promises between InterMune and you, whether oral or written, concerning the terms and conditions of your employment with InterMune. Any modification of this agreement will be
effective only if it is in writing and is signed by both you and the Chief Executive Officer of InterMune. 
 Alan, I am pleased
to extend this offer of employment to you, and hope that your association with InterMune will be successful and rewarding. Please indicate your acceptance of this offer by signing this letter below and returning the letter as soon as possible. A
copy of this letter is enclosed for your records. 
  

	
	 Sincerely,
  
 InterMune, Inc.

	
	/s/ Howard Simon
	 Howard Simon
 SVP,
HR & Corporate Services,
 Associate General Counsel and CCO

I understand and agree to the foregoing terms and conditions of employment with InterMune, Inc. 

 

	
	
	/s/ Alan Cohen
	Alan Cohen, M.D.

 Date 11/11/09Stock Option Agreement dated March 7, 2011

 Exhibit 4.1 
 PRO-PHARMACEUTICALS, INC. 
 NON-QUALIFIED STOCK OPTION AGREEMENT

 FOR 
 PETER G. TRABER, M.D. 
 1. Grant of Option. Pro-Pharmaceuticals, Inc., a
Nevada corporation (the “Company”), hereby grants, as of March 7, 2011 (the “Grant,” and such date, the “Grant Date”), to Peter G. Traber, M.D. (the “Optionee”) an option (the
“Option”) to purchase up to 5,000,000 shares of the Company’s common stock, $0.001 par value per share (the “Shares”), at an exercise price per share equal to $1.16 (the “Exercise Price”). The
Option shall be subject to the terms and conditions set forth herein. The Optionee hereby agrees to be bound by all of the terms and conditions hereof and all applicable laws and regulations. 
 2. Status of Shares. The Optionee hereby acknowledges that upon exercise of this Option the Shares shall constitute “restricted securities” within the meaning of Rule 144 under the
Securities Act of 1933 (the “Act”) and may not be offered and sold unless registered under the Act or pursuant to an applicable exemption from the registration requirements of the Act and applicable state law. 

3. Exercise Schedule. Except as otherwise provided in Sections 6 or 9 of this Agreement, the Option is exercisable in installments or as of
certain milestones as provided below, which shall be cumulative. To the extent that the Option has become exercisable with respect to a number of Shares as provided below, the Option may thereafter be exercised by the Optionee, in whole or in part,
at any time or from time to time prior to the expiration of the Option as provided herein. The following table indicates each date (the “Vesting Date”) upon which the Optionee shall be entitled to exercise the Option with respect to
the number of Shares granted as indicated beside the date, provided that the Continuous Service (defined below) of the Optionee continues through and on the applicable Vesting Date: 

 

			
	 Number of Shares
	  	 Vesting Date

	 750,000
	  	Grant Date
	 additional 625,000
	  	First anniversary of Grant Date
	 additional 625,000
	  	Second anniversary of Grant Date
	 additional 500,000
	  	Third anniversary of Grant Date
	 additional 500,000
	  	Fourth anniversary of Grant Date
	 additional 1,000,000
	  	Fifth anniversary of Grant Date

 Such
Vesting Dates notwithstanding, the Option becomes exercisable with respect to 1,750,000 of the foregoing 4,000,000 Shares upon the occurrence of milestone events as follows: 
 250,000 Shares as of the date the Company issues its audited financial statements for any financial year that reports gross revenues of at least fifty million dollars ($50,000,000) for such financial
year; 

 250,000 Shares as of the date of written approval from the U.S. Food and Drug Administration
(“FDA”) for each of up to two investigational drug applications, or INDs, filed by the Company for commencement of human clinical trials; 
 250,000 Shares as of the date of written approval from the FDA for each of up to two new drug applications, or NDAs, filed by the Company for any drug or drug delivery candidate; 

500,000 Shares as of the date on which the non-affiliate market capitalization of the Company (i.e., public float or “Market
Capitalization”) equals or exceeds one billion dollars ($1,000,000,000) on any ten (10) trading days within a twenty (20) consecutive trading day period by reference to the closing price of the Company’s common stock as
listed or quoted on any national securities exchange, OTC Bulletin Board or other well-recognized public trading market, as reported by Bloomberg L.P. or other widely-used service (the “Public Float Test”). 

The Option with respect to the remaining 1,000,000 of the 5,000,000 Shares is a “bonus,” the Vesting Dates for which are as
follows: 
 500,000 Shares as of the date the Public Float Test demonstrates that the Market Capitalization equals or exceeds
five billion dollars ($5,000,000,000), and 
 500,000 Shares as of the date the Public Float Test demonstrates that the Market
Capitalization equals or exceeds ten billion dollars ($10,000,000,000). 
 Except as otherwise specifically provided herein,
there shall be no proportionate or partial vesting in the periods prior to each Vesting Date, and all vesting shall occur only on the appropriate Vesting Date. Upon the termination of the Optionee’s continuous service (“Continuous
Service”) as Chief Executive Officer and President of the Company or any subsidiary or other related entity, or such other office as the Board of Directors (the “Board”) may approve any unvested portion of the Option shall
terminate and be null and void. 
 4. Method of Exercise. The vested portion of this Option shall be exercisable in whole or in
part in accordance with the exercise schedule set forth in Section 3 hereof by written notice which shall state the election to exercise the Option, the number of Shares in respect of which the Option is being exercised, and such other
representations and agreements as to the holder’s investment intent with respect to such Shares as may be required by the Company pursuant to the provisions of the Plan. Such written notice shall be signed by the Optionee and shall be delivered
in person or by certified mail to the Secretary of the Company. The written notice shall be accompanied by payment of the Exercise Price. This Option shall be deemed to be exercised after both (a) receipt by the Company of such written notice
accompanied by the Exercise Price and (b) arrangements that are satisfactory to the Committee (defined below) in its sole discretion have been made for Optionee’s payment to the Company of the amount, if any, that is necessary to be
withheld in accordance with applicable Federal or state withholding requirements. No Shares shall be issued pursuant to the Option unless and until such issuance and such exercise shall comply with all relevant provisions of applicable law,
including the requirements of any stock exchange upon which the Shares then may be traded. 

  
 2 

 5. Method of Payment. Payment of the Exercise Price shall be by any of the following, or a
combination thereof, at the election of the Optionee: (a) cash; (b) check; or (c) to the extent permitted by the Committee, with Shares owned by the Optionee, or the withholding of Shares that otherwise would be delivered to the
Optionee as a result of the exercise of the Option or (d) pursuant to a “cashless exercise” procedure, by delivery of a properly executed exercise notice together with such other documentation, and subject to such guidelines, as the
Committee shall require to effect an exercise of the Option and delivery to the Company by a licensed broker acceptable to the Company of proceeds from the sale of Shares, or (e) such other consideration or in such other manner as may be
determined by the Committee in its absolute discretion. 
 6. Termination of Option. 

(a) General. Any unexercised portion of the Option shall automatically and without notice terminate and become null and void
at the time on the tenth anniversary of the Grant Date. 
 (b) Cancellation. To the extent not previously
exercised, (i) the Option shall terminate immediately in the event of (A) the liquidation or dissolution of the Company, or (B) any reorganization, merger, consolidation or other form of corporate transaction in which the Company does
not survive or the Shares are exchanged for or converted into securities issued by another entity, or an affiliate of such successor or acquiring entity, unless the successor or acquiring entity, or an affiliate thereof, assumes the Option or
substitutes an equivalent option or right, and (ii) the Committee in its sole discretion may by written notice (“cancellation notice”) cancel, effective upon the consummation of any transaction that constitutes a Change in Control
(defined below), the Option (or portion thereof) that remains unexercised on such date. The Committee shall give written notice of any proposed transaction referred to in this Section 6(b) a reasonable period of time prior to the closing date
for such transaction (which notice may be given either before or after approval of such transaction), in order that the Optionee may have a reasonable period of time prior to the closing date of such transaction within which to exercise the Option
if and to the extent that it then is exercisable (including any portion of the Option that may become exercisable upon the closing date of such transaction). The Optionee may condition his exercise of the Option upon the consummation of a
transaction referred to in this Section 6(b). 
 7. Transferability. Unless otherwise determined by the Committee, the Option
granted hereby is not transferable otherwise than by will or under the applicable laws of descent and distribution, and during the lifetime of the Optionee the Option shall be exercisable only by the Optionee, or the Optionee’s guardian or
legal representative. In addition, the Option shall not be assigned, negotiated, pledged or hypothecated in any way (whether by operation of law or otherwise), and the Option shall not be subject to execution, attachment or similar process. Upon any
attempt to transfer, assign, negotiate, pledge or hypothecate the Option, or in the event of any levy upon the Option by reason of any execution, attachment or similar process contrary to the provisions hereof, the Option shall immediately become
null and void. The terms of this Option shall be binding upon the executors, administrators, heirs, successors and assigns of the Optionee. 

8. No Rights of Stockholders. Neither the Optionee nor any personal representative (or beneficiary) shall be, or shall have any of the rights and
privileges of, a stockholder of the 

  
 3 

 
Company with respect to any Shares purchasable or issuable upon the exercise of the Option, in whole or in part, prior to the date on which the Shares are issued. 

9. Acceleration of Exercisability of Option. 
 (a) Acceleration Upon Certain Terminations or Cancellations of Option. This Option shall become immediately fully exercisable in the event that, prior to the termination of the Option
pursuant to Section 6 hereof, (i) the Option is terminated pursuant to Section 6(b)(i) hereof, or (ii) the Company exercises its discretion to provide a cancellation notice with respect to the Option pursuant to
Section 6(b)(ii) hereof. 
 (b) Acceleration Upon Change in Control. This Option shall become immediately
fully exercisable in the event that, prior to the termination of the Option pursuant to Section 6 hereof, and during the Optionee’s Continuous Service, there is a “Change in Control”, as defined in any employment agreement to
which the Company and the Optionee are then parties. 
 10. No Right to Continued Employment. Neither the Option nor this Agreement shall
confer upon the Optionee any right to continued employment or service with the Company. 
 11. Law Governing. This Agreement shall be
governed in accordance with and governed by the internal laws of the Commonwealth of Massachusetts. 
 12. Administration;
Interpretation. The Option shall be administered by the Board or s committee designated by the Board (the “Committee”) to administer stock option or equity incentive plans adopted by the Company from time to time. The Optionee
hereby accepts as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under this Agreement, unless shown to have been made in an arbitrary and capricious manner. 

13. Notices. Any notice under this Agreement shall be in writing and shall be deemed to have been duly given when delivered personally or when
deposited in the United States mail, registered, postage prepaid, and addressed, in the case of the Company, to the Company’s Secretary at 7 Wells Avenue, Newton, Massachusetts 02459 Attn: Chief Financial Officer or Chief Operating Officer, or
if the Company should move its principal office, to such principal office, and, in the case of the Optionee, to the Optionee’s last permanent address as shown on the Company’s records, subject to the right of either party to designate some
other address at any time hereafter in a notice satisfying the requirements of this Section. 
 14. Section 409A. 

(a) It is intended that the Option awarded pursuant to this Agreement be exempt from Section 409A of the Code (“Section
409A”) because it is believed that (i) the Exercise Price may never be less than the fair market value of a Share on the Grant Date and the number of shares subject to the Option is fixed on the original Grant Date, (ii) the
transfer or exercise of the Option is subject to taxation under Section 83 of the Code and Treas. Reg. 1.83-7, and (iii) the Option does not include any feature for the deferral of compensation other than the deferral of recognition of
income until the exercise of the Option. The provisions of this Agreement shall be interpreted in a manner consistent with this intention, and the provisions of this Agreement 

  
 4 

 
may not be amended, adjusted, assumed or substituted for, converted or otherwise modified without the Optionee’s prior written consent if and to the extent that the Company believes or
reasonably should believe that such amendment, adjustment, assumption or substitution, conversion or modification would cause the award to violate the requirements of Section 409A. In the event that either the Company or the Optionee believes,
at any time, that any benefit or right under this Agreement is subject to Section 409A, then the Committee may (acting alone and without any required consent of the Optionee) amend this Agreement in such manner as the Committee deems necessary
or appropriate to be exempt from or otherwise comply with the requirements of Section 409A (including without limitation, amending the Agreement to increase the Exercise Price to such amount as may be required in order for the Option to be
exempt from Section 409A). 
 (b) Notwithstanding the foregoing, the Company does not make any representation to the
Optionee that the Option awarded pursuant to this Agreement is exempt from, or satisfy, the requirements of Section 409A, and the Company shall have no liability or other obligation to indemnify or hold harmless the Optionee or any Beneficiary
for any tax, additional tax, interest or penalties that the Optionee or any Beneficiary may incur in the event that any provision of this Agreement, or any amendment or modification thereof or any other action taken with respect thereto, that either
is consented to by the Optionee or that the Company reasonably believes should not result in a violation of Section 409A, is deemed to violate any of the requirements of Section 409A. 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 7th day of March, 2011. 

 

					
		 	COMPANY:
		
		 	 PRO-PHARMACEUTICALS, INC., a
 Nevada corporation

			
		 	By:	 	 /s/ Anthony D. Squeglia

		 	Name:	 	Anthony D. Squeglia
		 	Title:	 	Chief Financial Officer

 The Optionee
represents that he or she has reviewed the provisions this Agreement, is familiar with and understands its terms and provisions, and hereby accepts this Option subject to all of the terms and provisions of the Agreement. The Optionee further
represents that he or she has had an opportunity to obtain the advice of counsel prior to executing this Agreement. 
  

					
	Dated: March 7, 2011	 	OPTIONEE:
			
		 	By:	 	 /s/ Peter G. Traber, M.D.

		 		 	Peter G. Traber, M.D.

  
 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}]]